{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:53:36Z","timestamp":1781819616007,"version":"3.54.5"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate whether baseline glycosylated hemoglobin (HbA1C) levels play a predictive role in faricimab loading phase outcomes. In addition, the authors assessed the efficacy of faricimab loading phase for diabetic macular edema (DME).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      The authors conducted a retrospective, multicentric, interventional cohort study including 74 eyes, presenting with a central macular thickness (CMT) &gt;280\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m, visual acuity &gt; 20\/200, and optical coherence tomography\u2013based diagnosis of DME.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A statistically significant negative correlation was found between baseline HbA1c and the change in visual acuity after intravitreal faricimab injections (\u03c1 = \u22120.32,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.006). In multivariable regression, this association was not significant (\u03b2 \u2248 \u22120.026 logMAR per 1% HbA1c;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.26; \u2248 +1.3 letters\/1%). The correlation between baseline HbA1c and the change in CMT was not statistically significant (\u03c1 = +0.13,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.279). Visual acuity improved significantly from baseline to posttreatment (\u22120.18 \u00b1 0.22 \u0394LogMAR;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001). The mean baseline CMT (440.4 \u00b1 152.9\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m) significantly decreased (310.9 \u00b1 87.8\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001). The authors observed a significant reduction of hyperreflective foci (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.0001) and intraretinal fluid (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0014), and the subretinal fluid decreased from 29.7% to 10.8% after treatment (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.023).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Systemic glycemic status may influence functional outcomes, supporting the importance of maintaining optimal HbA1c levels in the overall management of diabetic patients. However, baseline HbA1c did not emerge as an independent predictor in this cohort. Notably, faricimab provided clear anatomical and functional benefits regardless of glycemic control, confirming its efficacy as a treatment for DME.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004820","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T22:00:15Z","timestamp":1772229615000},"page":"1266-1271","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["ASSOCIATION BETWEEN BASELINE GLYCATED HEMOGLOBIN LEVELS AND FUNCTIONAL AND ANATOMICAL OUTCOMES AFTER FARICIMAB LOADING PHASE IN DIABETIC MACULAR EDEMA"],"prefix":"10.1097","volume":"46","author":[{"given":"Alessandra","family":"Scampoli","sequence":"first","affiliation":[{"name":"Ophthalmology Department, Isola Tiberina Hospital \u2013 Gemelli Isola, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6961-8322","authenticated-orcid":false,"given":"Lorenzo","family":"Governatori","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Isola Tiberina Hospital \u2013 Gemelli Isola, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Solimeo","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Antonio Cardarelli Hospital, Napoli, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Plaitano","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, San Giovanni di Dio Ruggi d'Aragona Hospital, Salerno, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Turco","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, San Giovanni di Dio Ruggi d'Aragona Hospital, Salerno, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo Mario","family":"Carl\u00e0","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, \u201cA. De Rothschild\u201d Foundation Hospital, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Crincoli","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, \u201cA. De Rothschild\u201d Foundation Hospital, Paris, France."},{"name":"Ophthalmology Department, \u201cFondazione Policlinico Universitario A. Gemelli, IRCCS\u201d, Rome, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislao","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, \u201cFondazione Policlinico Universitario A. Gemelli, IRCCS\u201d, Rome, Italy; and"},{"name":"Ophthalmology Department, Catholic University \u201cSacro Cuore\u201d, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomaso","family":"Caporossi","sequence":"additional","affiliation":[{"name":"Ophthalmology Department, Isola Tiberina Hospital \u2013 Gemelli Isola, Rome, Italy;"},{"name":"Ophthalmology Department, Catholic University \u201cSacro Cuore\u201d, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20260618","first-page":"e79066","article-title":"The contributions of glycated hemoglobin (HbA1c), triglycerides, and hypertension to diabetic retinopathy: insights from a meta-analysis","volume":"17","author":"Alarbash","year":"2025","journal-title":"Cureus"},{"key":"R3-20260618","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N Engl J Med"},{"key":"R4-20260618","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","article-title":"Faricimab: first approval","volume":"82","author":"Shirley","year":"2022","journal-title":"Drugs"},{"key":"R5-20260618","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.3390\/jcm13102778","article-title":"Beyond VEGF: angiopoietin-tie signaling pathway in diabetic retinopathy","volume":"13","author":"Chen-Li","year":"2024","journal-title":"J Clin Med"},{"key":"R6-20260618","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.ophtha.2015.04.029","article-title":"Influence of glycosylated hemoglobin on the efficacy of ranibizumab for diabetic macular edema: a post hoc analysis of the RIDE\/RISE trials","volume":"122","author":"Bansal","year":"2015","journal-title":"Ophthalmology"},{"key":"R7-20260618","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jcjo.2017.10.008","article-title":"Effect of glycosylated hemoglobin on response to ranibizumab therapy in diabetic macular edema: real-world outcomes in 312 patients","volume":"53","author":"Shalchi","year":"2018","journal-title":"Can J Ophthalmol"},{"key":"R8-20260618","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.oret.2017.02.003","article-title":"Outcomes of diabetic macular edema patients by baseline hemoglobin A1c: analyses from VISTA and VIVID","volume":"1","author":"Singh","year":"2017","journal-title":"Ophthalmol Retina"},{"key":"R9-20260618","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1038\/s41598-024-55078-6","article-title":"The effect of glycosylated hemoglobin levels on the response to intravitreal dexamethasone implant for treating diabetic macular edema","volume":"14","author":"Lee","year":"2024","journal-title":"Sci Rep"},{"key":"R10-20260618","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1007\/s40123-023-00758-1","article-title":"Does HbA1c level or glomerular filtration rate affect the clinical response to endothelial growth factor therapy (ranibizumab or aflibercept) in diabetic macular edema? A real-life experience","volume":"12","author":"Debourdeau","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"R11-20260618","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12886-024-03432-7","article-title":"Association between the response of intravitreal antivascular endothelial growth factor injection and systemic factors of diabetic macular edema","volume":"24","author":"Lee","year":"2024","journal-title":"BMC Ophthalmol"},{"key":"R12-20260618","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3390\/medicina59040665","article-title":"Short-term outcomes of intravitreal faricimab injection for diabetic macular edema","volume":"59","author":"Kusuhara","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"R13-20260618","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3390\/medicina59061125","article-title":"Faricimab for diabetic macular edema in patients refractory to ranibizumab or aflibercept","volume":"59","author":"Ohara","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"R14-20260618","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1097\/IAE.0000000000004449","article-title":"Effects of faricimab loading phase on diabetic macular edema in real-world setting: an optical coherence tomography angiography study","volume":"45","author":"Scampoli","year":"2025","journal-title":"Retina"},{"key":"R15-20260618","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"R16-20260618","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"R18-20260618","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11892-018-1011-7","article-title":"Molecular mechanisms underlying the cardiovascular benefits of SGLT2i and GLP-1RA","volume":"18","author":"Khat","year":"2018","journal-title":"Curr Diab Rep"},{"key":"R19-20260618","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/db15-0443","article-title":"Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes","volume":"65","author":"Hern\u00e1ndez","year":"2016","journal-title":"Diabetes"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:01:21Z","timestamp":1781816481000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004820","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}